Gilead Sciences Inc. (GILD)

73.86
0.31 0.42
NASDAQ : Health Technology
Prev Close 74.17
Open 74.15
Day Low/High 73.72 / 74.80
52 Wk Low/High 64.27 / 89.54
Volume 1.75M
Avg Volume 6.30M
Exchange NASDAQ
Shares Outstanding 1.30B
Market Cap 98.03B
EPS 3.50
P/E Ratio 44.22
Div & Yield 2.28 (2.92%)

Latest News

Gilead Sciences To Release Third Quarter 2018 Financial Results On Thursday, October 25, 2018

Gilead Sciences To Release Third Quarter 2018 Financial Results On Thursday, October 25, 2018

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2018 financial results will be released on Thursday, October 25, after the market closes.

Gilead To Present Wide-Ranging New Data On Treatment And Diagnosis Of Liver Diseases At The Liver Meeting® 2018

Gilead To Present Wide-Ranging New Data On Treatment And Diagnosis Of Liver Diseases At The Liver Meeting® 2018

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that data from the company's liver disease research and development programs in nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), hepatitis B virus (HBV) infection and hepatitis...

Gilead Announces 96-Week Results From Phase 3 Study Of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 In Adults New To HIV Therapy

Gilead Announces 96-Week Results From Phase 3 Study Of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 In Adults New To HIV Therapy

Gilead Sciences, Inc. (Nasdaq: GILD) today announced 96-week results from a Phase 3, randomized, double-blinded study (Study 1489) evaluating the safety and efficacy of Biktarvy ® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg...

Hong Kong Department Of Health Approves Biktarvy(R) (bictegravir, Emtricitabine, Tenofovir Alafenamide)

Hong Kong Department Of Health Approves Biktarvy(R) (bictegravir, Emtricitabine, Tenofovir Alafenamide)

In Clinical Trials, Biktarvy Demonstrated High Efficacy and Zero Resistance Through 48 Weeks HONG KONG, Oct.

Kite And HiFiBiO Therapeutics Announce A Research Collaboration To Develop Technology For The Potential Discovery Of Neoantigen-Reactive T Cell Receptors (TCRs) For The Treatment Of Cancer

Kite And HiFiBiO Therapeutics Announce A Research Collaboration To Develop Technology For The Potential Discovery Of Neoantigen-Reactive T Cell Receptors (TCRs) For The Treatment Of Cancer

Kite, a Gilead Company (Nasdaq: GILD), and HiFiBiO Therapeutics, a biotechnology company focused on the discovery of therapeutic antibodies through single B cell screening and analysis, announced the companies have entered into a research collaboration...

Gilead Has Strengthened So Go Long and Add to Longs

Gilead Has Strengthened So Go Long and Add to Longs

Traders who are already long Gilead should buy more and if you are flat this is a good location to go long.

Total SA, Bluebird Bio, U.S. Silica Holdings: 'Mad Money' Lightning Round

Total SA, Bluebird Bio, U.S. Silica Holdings: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Total SA, Bluebird Bio, U.S. Silica Holdings, Nucor, International Paper, Nokia, Alibaba.

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

The Bears Have it Backwards: Cramer's 'Mad Money' Recap (Monday 9/24/18)

Jim Cramer says traders hate hearing about long-term investing because they want instant payoffs.

Gilead Subsidiary To Launch Authorized Generics Of Epclusa® (Sofosbuvir/Velpatasvir) And Harvoni® (Ledipasvir/Sofosbuvir) For The Treatment Of Chronic Hepatitis C

Gilead Subsidiary To Launch Authorized Generics Of Epclusa® (Sofosbuvir/Velpatasvir) And Harvoni® (Ledipasvir/Sofosbuvir) For The Treatment Of Chronic Hepatitis C

Gilead Sciences, Inc. (NASDAQ: GILD) announced today plans to launch authorized generic versions of Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni ® (ledipasvir 90mg/sofosbuvir 400mg), Gilead's leading treatments for chronic hepatitis C virus...

General Electric, Chevron, Manitowoc: 'Mad Money' Lightning Round

General Electric, Chevron, Manitowoc: 'Mad Money' Lightning Round

Jim Cramer takes a look at General Electric, Chevron, Manitowoc, Gilead Sciences, Encore Capital Group, Tower Semiconductor, Camping World, Kinder Morgan and more.

The Apple Revolution: Cramer's 'Mad Money' Recap (Thursday 9/13/18)

The Apple Revolution: Cramer's 'Mad Money' Recap (Thursday 9/13/18)

Jim Cramer says sustained, revolutionary innovation creates new demand where it didn't exist before.

How Gilead Call Prices Tripled Overnight

How Gilead Call Prices Tripled Overnight

These call buyers may have expected positive, bullish news in the coming weeks, on the belief that the pipeline for GILD is broad with a multitude of opportunities to serve as catalysts.

Gilead Sciences And Precision BioSciences Announce Collaboration To Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing

Gilead Sciences And Precision BioSciences Announce Collaboration To Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing

Gilead Sciences (Nasdaq: GILD) and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision's proprietary genome...

Gilead And Galapagos Announce Filgotinib Meets Primary And All Key Secondary Endpoints In First Phase 3 Study In Rheumatoid Arthritis

Gilead And Galapagos Announce Filgotinib Meets Primary And All Key Secondary Endpoints In First Phase 3 Study In Rheumatoid Arthritis

Gilead Sciences, Inc. (NASDAQ: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced that FINCH 2, a global, randomized, placebo-controlled, Phase 3 study of filgotinib, an investigational, selective JAK1 inhibitor, in adults with...

Gilead And Galapagos Announce TORTUGA Phase 2 Study Of Filgotinib In Ankylosing Spondylitis Achieves Primary Endpoint

Gilead And Galapagos Announce TORTUGA Phase 2 Study Of Filgotinib In Ankylosing Spondylitis Achieves Primary Endpoint

Gilead Sciences, Inc. (NASDAQ:GILD) and Galapagos NV (Euronext & NASDAQ:GLPG) today announced that the randomized, placebo-controlled Phase 2 TORTUGA study of filgotinib, an investigational, selective JAK1 inhibitor, achieved its primary efficacy endpoint...

Gilead Sciences To Present At The Morgan Stanley Global Healthcare Conference On Wednesday, September 12

Gilead Sciences To Present At The Morgan Stanley Global Healthcare Conference On Wednesday, September 12

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.

Laura Hamill - Executive Vice President, Worldwide Commercial Operations, Gilead Sciences (Photo: Business Wire)

Laura Hamill - Executive Vice President, Worldwide Commercial Operations, Gilead Sciences (Photo: Business Wire)

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Laura Hamill will join the company as Executive Vice President, Worldwide Commercial Operations, and will become a member of Gilead's senior leadership team.

Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization For The Treatment Of Relapsed Or Refractory DLBCL And PMBCL, After Two Or More Lines Of Systemic Therapy

Yescarta® (Axicabtagene Ciloleucel) Receives European Marketing Authorization For The Treatment Of Relapsed Or Refractory DLBCL And PMBCL, After Two Or More Lines Of Systemic Therapy

Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Commission (EC) has granted Marketing Authorization for Yescarta ® (axicabtagene ciloleucel) as a treatment for adult patients with relapsed or refractory diffuse large B-cell...

Here's Why You Should Invest in Immunotherapy Companies

Here's Why You Should Invest in Immunotherapy Companies

Immunotherapy may be the future of fighting cancer and companies are racing to capitalize on that. We spoke with the CEO of the Damon Runyon Cancer Research Foundation to find out why.

Gilead Sciences Announces Executive Promotions

Gilead Sciences Announces Executive Promotions

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Gregg Alton has been appointed Chief Patient Officer, a newly created role that will facilitate access to the company's medicines and increase focus on reaching patients.

3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick

3 Cheap Healthcare Stocks That Won't Make Your Portfolio Sick

The healthcare space continues to be ripe for investment opportunity. Here are three stocks that won't make your portfolio sick.

China National Drug Administration Approves Gilead's Genvoya® (Elvitegravir, Cobicistat, Emtricitabine And Tenofovir Alafenamide), A Single Tablet Regimen For The Treatment Of HIV-1 Infection

China National Drug Administration Approves Gilead's Genvoya® (Elvitegravir, Cobicistat, Emtricitabine And Tenofovir Alafenamide), A Single Tablet Regimen For The Treatment Of HIV-1 Infection

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Drug Administration (CNDA) has approved Genvoya ® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1...

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Gilead's Earnings Fail to Impress

Gilead's Earnings Fail to Impress

The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.

Gilead Sciences Announces Third Quarter 2018 Dividend

Gilead Sciences Announces Third Quarter 2018 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces Second Quarter 2018 Financial Results

Gilead Sciences Announces Second Quarter 2018 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2018.

Gilead Sciences Announces CEO John F. Milligan To Step Down

Gilead Sciences Announces CEO John F. Milligan To Step Down

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F.

TheStreet Quant Rating: C+ (Hold)